This Tiny Biopharma Has Been Bucking The Downtrend


What : Shares of Amarin Corp. are up by over 4% a little past the midway point through 2016,according to data from S&P Global Market Intelligence . Before last Friday's Brexit sell-off, Amarin' shares were up by double-digits for the year, fueled by the drugmaker's increasing sales of its highly refined fish oil pill, Vascepa, aimed at patients with severely high triglyceride levels.



from Biotech News